The U.S. Food and Drug Administration today announced the issuance of 30 warning letters to telehealth companies for making false and misleading claims regarding compounded GLP-1 products offered on their websites.
Similar Posts
CDER and CBER accept first submission to ISTAND Pilot Program
FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have accepted the agency’s first submission into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.PlantBased Innovations Issues Allergy Alert on Undeclared Almond in H-E-B Dairy-Free Coconut Yogurt, Strawberry Flavor
PlantBased Innovations, of Leominster, MA, is recalling Higher Harvest by H-E-B Dairy-Free Coconut Yogurt, Strawberry flavor because the product may contain undeclared almond. People who have an allergy or severe sensitivity to almonds run the risk of serious or life-threatening allergic reaction ifFarmaKeio Outsourcing LLC. Southlake, TX. 483 issued 09/05/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 09/05/2025
Short Title (70 char) FarmaKeio Outsourcing LLC. Southlake, TX. 483 issued 09/05/2025
FEI Number 3014982757
Firm Name FarmaKeio Outsourcing LLC
Record Type 483
State TX
Establishment Type OutsourcingCentral Admixture Pharmacy Services, Inc., (CAPS), Livonia, MI, 483 Issued 2/28/2013
Central Admixture Pharmacy Services, Inc., (CAPS), Livonia, MI, 483 Issued 2/28/2013Drug Development Tool Qualification Process: Transparency Provisions
Under the 21st Century Cures Act enacted on December 13, 2016, the new section 507 Qualification of Drug Development Tools was added to the Federal Food, Drug, and Cosmetic Act and formally establishes an updated, multi-stage process for DDT qualification. This process includes three submission milFDA Approves First Over-the-Counter Naloxone Nasal Spray
The U.S. Food and Drug Administration approved the first naloxone nasal spray product available without a prescription.